Data supports further development of CYT-338
in relapsed/refractory multiple myeloma
AVENTURA,
Fla. and NATICK, Mass., June 10,
2022 /PRNewswire/ -- Cytovia Therapeutics, Inc., a
biopharmaceutical company empowering natural killer (NK) cells to
fight cancer through stem cell engineering and multispecific
antibodies, announced today that the novel data it is presenting at
the European Hematology Association's annual congress in
Vienna, Austria on June
10th, 2022 is now available on both the EHA and Cytovia
websites.
For details on in-person poster presentations, please see the
following:
Title: NOVEL MULTIFUNCTIONAL TETRAVALENT CD38 NKP46 FLEX-NK
ENGAGERS ACTIVELY TARGET AND KILL MULTIPLE MYELOMA CELLS
Session Title: Poster session
Session date and time: Friday, June 10 2022 - 16:30 - 17:45 CEST
Final Abstract Code: P842
Abstract Link:
https://library.ehaweb.org/eha/2022/eha2022-congress/357704/antonio.arulanandam.novel.multifunctional.tetravalent.cd38.nkp46.flex-nk.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DNK
Summary: CYT-338 is a tetravalent IgG1-like multifunctional NK
cell engager antibody with a novel FLEX-linker that simultaneously
binds CD38-expressing cells and NK cells via the activating
receptor NKp46. CYT-338 pharmacokinetics and pharmacodynamics was
studied using in vitro and in vivo multiple myeloma models. CYT-338
showed 3-fold higher dose-dependent binding to CD38 expressing MM
cell lines compared to daratumumab. Epitope mapping studies
indicated that CYT-338 binds to a different CD38 epitope compared
to daratumumab. CYT-338 showed greater dose dependent NK cell
redirected cytolysis, degranulation, and cytokine production
against MM1S cells compared to daratumumab. CYT-338 showed minimal
immune subset depletion, NK cell fratricide, and cytokine release
compared to daratumumab in vitro. CYT-338 showed tumor growth
inhibition and improved survival in in vivo models of multiple
myeloma. These results support further development of CYT-338 as a
therapeutic for targeting CD38 expressing multiple myeloma cells
distinct from daratumumab.
About Cytovia Therapeutics
Cytovia Therapeutics aims
to accelerate patient access to transformational cell therapies and
immunotherapies, addressing several of the most challenging unmet
medical needs in cancer. Cytovia focuses on harnessing the innate
immune system by developing complementary and disruptive NK-cell
and NK-engager antibody platforms. The company is developing three
types of iPSC-derived (or iNK) cells: unedited iNK cells, TALEN®
gene-edited iNK cells with improved function and persistence, and
TALEN® gene-edited iNK cells with chimeric antigen receptors
(CAR-iNKs) to improve tumor-specific targeting. The second
complementary cornerstone technology is a quadrivalent
multifunctional antibody platform designed to engage natural killer
cells by targeting NKp46 using Cytovia's proprietary Flex-NK™
technology.
These two technology platforms are being used to develop
treatment for patients with solid tumors such as HCC and
glioblastoma as well as hematological malignancies such as
refractory multiple myeloma.
Headquartered in Aventura, FL., Cytovia has research and
development laboratories in Natick, MA., and a GMP cell
manufacturing facility in Puerto Rico. The company's own
R&D work is augmented through scientific partnerships with
Cellectis, CytoImmune, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell
Foundation and the University of California San
Francisco (UCSF).
Cytovia has recently formed CytoLynx Therapeutics, a strategic
partnership focused on research and development, manufacturing, and
commercialization activities in Greater China and
beyond.
Find out more at www.cytoviatx.com and follow us
on Facebook, Twitter, LinkedIn, YouTube,
and Instagram.
About CD38
Cluster of differentiation 38 (CD38) is a
type II receptor membrane glycoprotein that plays a role in cell
adhesion, migration, and signal transduction.
Additionally, CD38 is an ectoenzyme involved in
generation of nucleotide metabolites, such as ADP-Ribose
that regulate cell metabolism. CD38 is highly expressed in
multiple myeloma (MM) on malignant plasma cells and is also
moderately expressed on normal T, B, NK and myeloid cells.
Antibodies targeting CD38, such as daratumumab and isatuximab, are
FDA approved for the treatment of MM as monotherapy and in
combination.
Additional Information and Where to Find It
Isleworth
Healthcare Acquisition Corp. ("Isleworth") (NASDAQ: ISLE)
intends to file a registration statement on Form S-4 with the
Securities Exchange Commission (the "SEC"), which will include a
proxy statement/prospectus, that will be both the proxy statement
to be distributed to holders of Isleworth's common stock in
connection with its solicitation of proxies for the vote by
Isleworth's stockholders with respect to the proposed business
combination pursuant to a Merger Agreement and Plan of
Reorganization entered into on April 26, 2022, by and between
Isleworth, Cytovia Holdings, Inc., the parent company of
Cytovia Therapeutics ("Cytovia"), IHAC First Merger Sub Inc., a
direct, wholly-owned subsidiary of Isleworth, IHAC Second Merger
Sub LLC, direct, wholly-owned subsidiary of Isleworth, and
Isleworth Healthcare Sponsor I, LLC (the "Business Combination")
and other matters as may be described in the registration
statement, as well as the prospectus relating to the offer and sale
of the securities to be issued in the Business Combination. After
the registration statement is declared effective, Isleworth will
mail a definitive proxy statement/prospectus and other relevant
documents to its stockholders. This communication does not contain
all the information that should be considered concerning the
Business Combination and is not intended to form the basis of any
investment decision or any other decision in respect of the
Business Combination. Isleworth's stockholders and other interested
persons are advised to read, when available, the preliminary proxy
statement/prospectus included in the registration statement and the
amendments thereto and the definitive proxy statement/prospectus
and other documents filed in connection with the Business
Combination, as these materials will contain important information
about Cytovia, Cytovia Therapeutics, Isleworth and the Business
Combination. When available, the definitive proxy
statement/prospectus and other relevant materials for the Business
Combination will be mailed to stockholders of Isleworth as of a
record date to be established for voting on the Business
Combination. Stockholders will also be able to obtain copies of the
preliminary proxy statement, the definitive proxy statement and
other documents filed with the SEC, without charge, once available,
at the SEC's website at www.sec.gov, or by directing a request
to Isleworth's secretary at 360 Central Avenue, First Central
Tower, Suite #800, St. Petersburg,
Florida 33701.
Participants in the Solicitation
Isleworth, Cytovia
and their respective directors, executive officers and other
members of their management and employees, under SEC rules, may be
deemed to be participants in the solicitation of proxies from
Isleworth stockholders in connection with the proposed transaction.
Investors and security holders may obtain more detailed information
regarding the names, affiliations and interests of Isleworth
directors and executive officers in Isleworth's Annual Report on
Form 10-K for the fiscal year ended December 31, 2021, which
was filed with the SEC on March 29, 2022. To the extent that
holdings of Isleworth securities have changed since the filing of
the Annual Report on Form 10-K, such changes have been or will be
reflected on Statements of Change in Ownership on Form 4 filed with
the SEC. Information regarding the persons who may, under SEC
rules, be deemed participants in the solicitation of proxies of
Isleworth stockholders in connection with the proposed transaction
will be set forth in the proxy statement/information
statement/prospectus for the proposed transaction when available.
Information concerning the interests of Isleworth participants in
the solicitation, which may, in some cases, be different than those
of Isleworth Healthcare Acquisition Corp.'s equity holders
generally, will be set forth in the proxy statement/information
statement/prospectus relating to the proposed transaction when it
becomes available.
Forward Looking Statements
This press release may
contain forward-looking statements, which may be identified by
words such as "aims," "anticipates," "believes," "could,"
"estimates," "expects," "forecasts," "goal," "intends," "may,"
"plans," "possible," "potential," "seeks," "will" and variations of
these words or similar expressions that are intended to identify
forward-looking statements, although not all forward-looking
statements contain these words. Forward-looking statements in this
press release include, but are not limited to, statements regarding
the potential of Cytovia's FLEX-NK multifunctional engager antibody
and iNK cells. Cytovia may not actually achieve the plans,
intentions or expectations disclosed in these forward-looking
statements, and you should not place undue reliance on these
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
these forward-looking statements as a result of various factors,
including whether the outcome of preclinical studies will be
predictive of clinical trial results. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Cytovia expressly disclaims any obligation to
update any forward-looking statements contained herein, whether
because of any new information, future events, changed
circumstances or otherwise, except as otherwise required by
law.
No Offer or Solicitation
This communication is for
informational purposes only and is neither an offer to purchase,
nor a solicitation of an offer to sell, subscribe for or buy, any
securities or the solicitation of any vote in any jurisdiction
pursuant to the Business Combination or otherwise, nor shall there
be any sale, issuance or transfer or securities in any jurisdiction
in contravention of applicable law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cytovia-therapeutics-presents-antitumor-activity-of-its-cd38-targeting-flex-nk-cell-engager-antibody-at-eha-2022-congress-301565565.html
SOURCE Cytovia Therapeutics